AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36340667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine injection of autologous PRP
Number of subjects: 118
Study 36340667 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of fetal transfer without intrauterine PRP injection
Number of subjects: 118
Study 32041649 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 32041649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35410938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXY) spray (24 IU)
Number of subjects: 62
Study 35410938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) spray plus oral naltrexone (NTX) (50 mg)
Number of subjects: 62
Study 34268680 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week supervised exercise program (strength and aerobic training) starting 7-14 days after surgery
Number of subjects: 80
Study 34268680 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 80
Study 35329972 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with a new nutritional product developed by the Grand Fontaine Laboratories
Number of subjects: 0
Study 35329972 — intervention group
Group type: COMPARATOR
Intervention: Standard renal dietary advice (Control)
Number of subjects: 0
Study 32126557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy-enhanced skin self-examinations (SSEs)
Number of subjects: 28
Study 32126557 — intervention group
Group type: COMPARATOR
Intervention: Naked-eye skin self-examinations (SSE)
Number of subjects: 28
Study 32762573 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report logbooks of exercise performance
Number of subjects: 15
Study 33728044 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicines and Alcohol Consultation (MAC) intervention
Number of subjects: 51
Study 33728044 — intervention group
Group type: COMPARATOR
Intervention: Control group (consultations as usual)
Number of subjects: 51
Study 33728044 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up calls (telephone)
Number of subjects: 51
Study 33728044 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection methods (telephone and postal)
Number of subjects: 51
Study 33728044 — intervention group
Group type: EXPERIMENTAL
Intervention: External researcher follow-up
Number of subjects: 51
Study 35064716 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg for 7 days
Number of subjects: 59
Study 35064716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 35064716 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg single dose
Number of subjects: 59
Study 35064716 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plasma levels
Number of subjects: 59
Study 33736756 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 100
Study 33736756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33736756 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (Ischemic)
Number of subjects: 100
Study 33736756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Ischemic)
Number of subjects: 100
Study 33736756 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (Nonischemic)
Number of subjects: 100
Study 33736756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Nonischemic)
Number of subjects: 100
Study 32058140 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based audio guidance pelvic floor muscle training
Number of subjects: 108
Study 32058140 — intervention group
Group type: COMPARATOR
Intervention: Conventional home-based pelvic floor muscle training
Number of subjects: 108
Study 35448154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm (8 phone counseling sessions + 8 weeks of nicotine replacement therapy)
Number of subjects: 818
Study 35448154 — intervention group
Group type: COMPARATOR
Intervention: Minimal arm (3 sessions + 2 weeks of nicotine replacement therapy)
Number of subjects: 818
Study 32245369 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐HPV test
Number of subjects: 469
Study 32245369 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection under Acetic Acid (VIA)
Number of subjects: 469
Study 32245369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 469
Study 34052928 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Number of subjects: 45
Study 34052928 — intervention group
Group type: EXPERIMENTAL
Intervention: Red laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Number of subjects: 45
Study 34052928 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study 33722758 — intervention group
Group type: EXPERIMENTAL
Intervention: Greedy Rabbit exergame (experimental group)
Number of subjects: 60
Study 33722758 — intervention group
Group type: COMPARATOR
Intervention: Placebo version of Greedy Rabbit (control group)
Number of subjects: 60
Study 33571562 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 42
Study 33571562 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 42
Study 33571562 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (NET)
Number of subjects: 42
Study 33821439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) with a load of 70% of maximum inspiratory pressure (MIP), 3 sets of 30 repetitions with 1-min intervals
Number of subjects: 40
Study 33821439 — intervention group
Group type: COMPARATOR
Intervention: Placebo group performing IMT without load
Number of subjects: 40
Study 33821439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 40
Study 34152784 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted loss-framed messaging
Number of subjects: 457
Study 34152784 — intervention group
Group type: COMPARATOR
Intervention: Standard loss-framed messaging
Number of subjects: 457
Study 35821731 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Treatment
Number of subjects: 25
Study 35821731 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 25
Study 35212136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Purified Protein Derivative (PPD) 10 IU (0.1 ml)
Number of subjects: 120
Study 35212136 — intervention group
Group type: COMPARATOR
Intervention: Intralesional Zinc Sulfate 2%
Number of subjects: 120
Study 32356170 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection (SCI)
Number of subjects: 66
Study 32356170 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection plus suprascapular nerve block (SSNB)
Number of subjects: 66
Study 32356170 — intervention group
Group type: COMPARATOR
Intervention: Control group (SCI)
Number of subjects: 66
Study 33270009 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus static text messages (n=59)
Number of subjects: 235
Study 33270009 — intervention group
Group type: EXPERIMENTAL
Intervention: One-intervention arm (n=57)
Number of subjects: 235
Study 33270009 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-intervention arm (n=58)
Number of subjects: 235
Study 33270009 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes in Australia
Number of subjects: 235
Study 33270009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement treatment in England
Number of subjects: 235
Study 33270009 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Planning and Prompting Protocol coping strategies
Number of subjects: 235
Study 33270009 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 235
Study 33439419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=70)
Number of subjects: 173
Study 33439419 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=103)
Number of subjects: 173
Study 33170261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Benzoate (500 mg twice daily)
Number of subjects: 100
Study 33170261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Social distancing intervention
Number of subjects: 0
Study 34825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization-based inference methods
Number of subjects: 0
Study 34435202 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure (HA)
Number of subjects: 483
Study 32438300 — intervention group
Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN) for 4 weeks
Number of subjects: 62
Study 32438300 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (SEN)
Number of subjects: 62
Study 34468080 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (200 mg once daily for 11 days)
Number of subjects: 27
Study 34501669 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Environment (VE) rehabilitation program
Number of subjects: 35
Study 34501669 — intervention group
Group type: COMPARATOR
Intervention: Standard paper–pencil treatment
Number of subjects: 35
Study 34585443 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 7714
Study 34585443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7714
Study 35293973 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition (E‐SPN) starting on day 3 after surgery
Number of subjects: 230
Study 35293973 — intervention group
Group type: COMPARATOR
Intervention: Late supplemental parenteral nutrition (L‐SPN) starting on day 8 after surgery
Number of subjects: 230
Study 35293973 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐SPN
Number of subjects: 230
Study 33710368 — intervention group
Group type: EXPERIMENTAL
Intervention: UBR5 expression combined with CD163+ tumor-associated macrophages (TAMs)
Number of subjects: 310
Study 33710368 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of UBR5 and CD163
Number of subjects: 310
Study 33710368 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of UBR5 and CD163 into clinical indicators TNM stage or SSIGN
Number of subjects: 310
Study 33710368 — intervention group
Group type: COMPARATOR
Intervention: UBR5 expression
Number of subjects: 310
Study 33710368 — intervention group
Group type: COMPARATOR
Intervention: CD163 expression
Number of subjects: 310
Study 32113839 — intervention group
Group type: EXPERIMENTAL
Intervention: GCs + LEF (20 mg/day)
Number of subjects: 66
Study 32113839 — intervention group
Group type: COMPARATOR
Intervention: GCs monotherapy
Number of subjects: 66
Study 36094619 — intervention group
Group type: EXPERIMENTAL
Intervention: AUT00206
Number of subjects: 14
Study 36094619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 32141188 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating blog intervention (n = 42)
Number of subjects: 84
Study 32141188 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 84
Study 33272923 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental smoking practices (number of smokers in the home)
Number of subjects: 213
Study 33272923 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental smoking practices (smoking inside the house)
Number of subjects: 213
Study 33272923 — intervention group
Group type: EXPERIMENTAL
Intervention: Families who smoke only outside the home
Number of subjects: 213
Study 36232122 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with intramuscular injections of pIRES/VEGF165/HGF plasmids and 1 month of ANG-1 plasmids
Number of subjects: 24
Study 36232122 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 24
Study 36232122 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 34894884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based attention training (MBAT)
Number of subjects: 0
Study 34894884 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education (LifeEd)
Number of subjects: 0
Study 32949941 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR)
Number of subjects: 90
Study 32949941 — intervention group
Group type: COMPARATOR
Intervention: iPad control condition
Number of subjects: 90
Study 35244019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic treatment of Asherman syndrome
Number of subjects: 43
Study 33781673 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 253
Study 33781673 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 253
Study 33781673 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-presential consultations
Number of subjects: 253
Study 33781673 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact preference
Number of subjects: 253
Study 35619138 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy briefs signed by the African donor organization (financial authority)
Number of subjects: 0
Study 35619138 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy briefs signed by the African university (scientific authority)
Number of subjects: 0
Study 35619138 — intervention group
Group type: COMPARATOR
Intervention: Policy briefs signed by North American/European organizations (financial and scientific authority)
Number of subjects: 0
Study 33280497 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP17 overexpression group
Number of subjects: 3
Study 33280497 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP17 knockdown group
Number of subjects: 3
Study 33280497 — intervention group
Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 3
Study 35302301 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk (Yakult)
Number of subjects: 34
Study 35302301 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic powder (enKor-D)
Number of subjects: 34
Study 35302301 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 34
Study 32876780 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 798
Number of subjects: 311
Study 32876780 — intervention group
Group type: COMPARATOR
Intervention: Rituximab reference product (RP)
Number of subjects: 311
Study 32876780 — intervention group
Group type: COMPARATOR
Intervention: Rituximab US transitioning to ABP 798
Number of subjects: 311
Study 32876780 — intervention group
Group type: COMPARATOR
Intervention: Rituximab EU
Number of subjects: 311
Study 36117569 — intervention group
Group type: EXPERIMENTAL
Intervention: Active non-invasive transcutaneous electrical stimulation of greater occipital nerve (NITESGON)
Number of subjects: 100
Study 36117569 — intervention group
Group type: COMPARATOR
Intervention: Sham NITESGON
Number of subjects: 100
Study 36117569 — intervention group
Group type: COMPARATOR
Intervention: Active NITESGON with local anesthesia
Number of subjects: 100
Study 36117569 — intervention group
Group type: COMPARATOR
Intervention: Active NITESGON on the C5/C6 nerve
Number of subjects: 100
Study 33402584 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost (21 Gy in three fractions) combined with whole pelvic radiotherapy (RT) (50 Gy in 25 fractions)
Number of subjects: 34
Study 33402584 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost
Number of subjects: 34
Study 35078490 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided SBRT of the primary pancreatic cancer (pPCa) with 5 × 6.6 Gy at 80% isodose with continuation of SoC-CT thereafter
Number of subjects: 92
Study 35078490 — intervention group
Group type: COMPARATOR
Intervention: Standard of care chemotherapy (SoC-CT) without SBRT
Number of subjects: 92
Study 33327737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice/day
Number of subjects: 794
Study 33327737 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel monotherapy
Number of subjects: 794
Study 35723920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic vitreolysis
Number of subjects: 30
Study 35723920 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy
Number of subjects: 30
Study 32914197 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomedullary phase CT
Number of subjects: 177
Study 32914197 — intervention group
Group type: COMPARATOR
Intervention: Nephrographic phase CT
Number of subjects: 177
Study 32914197 — intervention group
Group type: COMPARATOR
Intervention: Non-contrast-enhanced CT
Number of subjects: 177
Study 33952741 — intervention group
Group type: EXPERIMENTAL
Intervention: Grains of Paradise (GP) extract (40 mg/d)
Number of subjects: 9
Study 33952741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 32212979 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs with SensiumVitals in addition to intermittent monitoring
Number of subjects: 0
Study 32212979 — intervention group
Group type: COMPARATOR
Intervention: Intermittent vital signs monitoring alone
Number of subjects: 0
Study 32212979 — intervention group
Group type: EXPERIMENTAL
Intervention: SensiumVitals in addition to intermittent monitoring
Number of subjects: 0
Study 36164099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 20mg PO d1-21 of a 28-d cycle + rituximab IV 375mg/m2/week for 12 cycles (R2)
Number of subjects: 394
Study 36164099 — intervention group
Group type: COMPARATOR
Intervention: Rituximab maintenance for 18 months
Number of subjects: 394
Study 36164099 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction phase (R2)
Number of subjects: 394
Study 32541510 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuanhu Zhitong dropping pills
Number of subjects: 60
Study 32541510 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium sustained-release capsule
Number of subjects: 60
Study 34986007 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Radical Cystectomy (RARC) with intracorporeal urinary diversion
Number of subjects: 116
Study 34986007 — intervention group
Group type: COMPARATOR
Intervention: Open Radical Cystectomy (ORC)
Number of subjects: 116
Study 33970295 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction (DB ACLR)
Number of subjects: 57
Study 33970295 — intervention group
Group type: COMPARATOR
Intervention: Anatomic single-bundle ACL reconstruction (SB ACLR)
Number of subjects: 57
Study 32857151 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term integrated palliative care (SIPC)
Number of subjects: 350
Study 32857151 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 350
Study 32857151 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPC
Number of subjects: 350
Study 616081112 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 5mg/ml
Number of subjects: 20
Study 616081112 — intervention group
Group type: COMPARATOR
Intervention: Topical bromfenac 9mg/ml
Number of subjects: 20
Study 34610775 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive occupational intervention (REBOI) for 12 weeks
Number of subjects: 168
Study 34610775 — intervention group
Group type: COMPARATOR
Intervention: Conventional means of counseling (waitlisted control group)
Number of subjects: 168
Study 33836778 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor G2 (IG2)
Number of subjects: 0
Study 33836778 — intervention group
Group type: COMPARATOR
Intervention: Chlorfenapyr treated net
Number of subjects: 0
Study 33836778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both insecticide components of IG2
Number of subjects: 0
Study 33836778 — intervention group
Group type: COMPARATOR
Intervention: WHO susceptibility tests with pyrethroid papers
Number of subjects: 0
Study 32451827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (15 mg/kg/dose)
Number of subjects: 50
Study 32451827 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (10 mg/kg/dose)
Number of subjects: 50
Study 34216423 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic clowning
Number of subjects: 166
Study 34216423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166
Study 32057000 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone acetate 0.1%
Number of subjects: 62
Study 32057000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 62
Study 32820548 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 32820548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study 34360051 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimators
Number of subjects: 0
Study 34360051 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequentist estimators
Number of subjects: 0
Study 34360051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for prognostic baseline covariates
Number of subjects: 0
Study 34360051 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model
Number of subjects: 0
Study 32164118 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial nerve monitoring during acoustic schwannoma resection
Number of subjects: 80
Study 36102776 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated oncogeriatric care
Number of subjects: 154
Study 36102776 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 33622882 — intervention group
Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC)
Number of subjects: 88
Study 33622882 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 88
Study 35758374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Resveratrol (500 mg/d)
Number of subjects: 160
Study 35758374 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-dose Resveratrol (250 mg/d)
Number of subjects: 160
Study 35758374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Resveratrol (125 mg/d)
Number of subjects: 160
Study 35758374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 33883102 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals served in kindergartens (10-day menus)
Number of subjects: 1746